BestStocksBeta
Market closed · Next open: Friday 9:30 AM ET
Last update: Oct 29, 2026, 6:16 PM ET
Illumina, Inc.
$290.06▲ 0.44% today
Market Closed

Why Illumina, Inc. (ILMN) stock moved

Updated Oct 30, 2026

Illumina, Inc. (ILMN) shares rose 0.4% to $290.06 as of October 30, 2026, a slight gain from the prior close of $288.79. BestStocks flagged the session as a major change for ILMN. The move is tied to an earnings beat. Below, we break down what changed for ILMN, why it matters for investors, how the stock reacted, and the catalysts on the calendar.

What happened

Earnings Beat

Illumina, Inc. (ILMN) reported EPS of $1.62 vs. consensus estimate of $1.36, beating by 19.1% for Q3 FY2026. Monitor Q3 FY2026 revenue, gross margin, and full-year guidance for visibility into whether the beat reflects sustainable business momentum or one-time items.

This summary describes the catalyst and move as first detected on Oct 29, 2026, 4:39 PM EDT; the stock has continued trading since, so the current price and percentage move (shown above) may be larger or smaller than the figures here.
Material / EarningsLow confidence
Rel. volume
0.8×
Below Avg
Vs peers
—
No comparable peers
Market cap
$43.8B
NASDAQ Global Select
Analyst target
$253
-12.9% vs price
Price chart
Sep 29 – Oct 29
ENNVVNNNNEV$262$278$294Sep 29Oct 7Oct 14Oct 22Oct 29
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details

What it means for Illumina, Inc. investors

For Illumina, Inc. investors, the balance of recent signals points to a bullish shift. On the constructive side: Earnings beat with positive market reaction; Positive 0.4% session move. Weighing against that: Illumina shares fell 6.14% to $265.48 on light volume (0.65x average) ahead of Q3 earnings scheduled for late October. Wall Street's consensus price target sits at $252.73, implying -12.9% downside from $290.06. Over the past 90 days analysts logged 1 upgrade and 0 downgrades. BestStocks rates the overall signal quality low (49/100). With earnings roughly 97 days out, the next report is the most likely near-term test of the move.

ILMN price reaction

ILMN last traded at $290.06, up $1.27 (+0.44%) from the previous close of $288.79. The session traded on 0.8× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $262.54 and $293.69, and it currently sits about 88% of the way up that band.

Bullish and bearish analyst opinions on Illumina, Inc. (ILMN)

Latest catalyststrengthens the bull case
The latest catalyst — an earnings beat the market rewarded — it strengthens the bull case.

The consensus analyst price target on Illumina, Inc. (ILMN) is $252.73, 12.9% below the recent $290.06. Over the past 90 days analysts logged 1 upgrade, 11 maintains, and 0 downgrades. Here is how the bullish and bearish cases on ILMN line up.

The bullish case

  • The Street's most bullish target is $305.00 (+5.2%).
  • 1 analyst upgrade in the past 90 days, most recently UBS to Buy (2026-09-09).
  • Earnings beat with positive market reaction.
  • Positive 0.4% session move.
  • Illumina rallied 3.28% to $229.59, driven by a newly announced five-year collaboration with Novacyt expanding its sequencing platform into clinical diagnostics, combined with institutional positioning ahead of its S&P 500 index inclusion on September 21 (per web synthesis corroborated by Yahoo Finance reporting).

The bearish case

  • The consensus analyst price target of $252.73 sits 12.9% below the recent $290.06, so the average target sees limited room to run.
  • The most bearish analyst target is $155.00 (-46.6%).
  • Illumina shares fell 6.14% to $265.48 on light volume (0.65x average) ahead of Q3 earnings scheduled for late October.
Bull vs bear balanceBullish Shift
BearishNeutralBullish
The latest catalyst moved the balance toward the bulls — the hollow tick marks where it sat before.

Weighing both sides, BestStocks' composite read of recent signals is bullish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.

Analyst price targets and ratings are FMP consensus figures as of Oct 29, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.

Analyst expectations
Consensus target: $253-12.9%
↑ 1 upgrades= 11 maintains
Canaccord Genuity maintained Hold · 2026-10-19
SEC filings watch
8-K2026-10-29
Material event — review for impact
high
8-K2026-10-13
Material event — review for impact
high
8-K2026-08-17
Material event — review for impact
high
8-K2026-08-13
Material event — review for impact
high
Peer context
ILMN+0.4%

Previous notable changes for ILMN

News2026-10-29+0.4%
Illumina reported Q3 2026 revenue of $1.13 billion, up 4.2% year-over-year.
News2026-10-27+3.1%
Illumina management will participate in fireside chat at Jefferies Global Healthcare Conference on November 17.
Risk2026-10-22-4.8%via zacks.com ↗
Illumina shares fell 6.14% to $265.48 on light volume (0.65x average) ahead of Q3 earnings scheduled for late October. No specific negative catalyst emerged intraday; recent analyst commentary from Zacks and Seeking Alpha had highlighted strong clinical demand and NovaSeq X momentum as potential performance drivers. The decline occurs in the absence of fresh company news, suggesting investor caution before the earnings release.
Valuation2026-10-21+5.6%via PR Newswire ↗
Illumina rose 6.16% to $284.44 on analyst price-target upgrades—including Canaccord Genuity raising its target to $300—combined with positive momentum ahead of the October 29 earnings report, which carries a strong +9.16% Earnings ESP signal and a consensus EPS estimate of $1.36. The company also announced an expansion of its BioInsight Platform with new genomics AI software (PR Newswire), reinforcing investor enthusiasm around multiomics and AI applications in gene sequencing.

In-depth ILMN event analyses

Permanent, dated analyses of ILMN's most significant sessions.
Upcoming catalysts & outlook
Next earnings
2027-02-04 (est.)
in 97 days
Thesis shift
Bullish Shift
bullish signal
Risk level
Medium
from change events

Frequently asked questions about ILMN

Why did Illumina, Inc. (ILMN) stock move?

ILMN rose 0.4% to $290.06. The move is associated with an earnings beat.

How much did ILMN stock rise?

ILMN gained 0.44% ($1.27) versus the prior close of $288.79, last trading at $290.06 on 0.8× average volume.

When is Illumina, Inc.'s next earnings date?

ILMN's next earnings report is estimated for 2027-02-04 — about 97 days away.

What is the analyst price target for ILMN?

The consensus analyst price target for ILMN is $252.73, about 12.9% below the current $290.06. Over the past 90 days, analysts recorded 1 upgrade, 11 maintains, and 0 downgrades.

How BestStocks tracks ILMN

This page is generated automatically by BestStocks' change-detection system after an earnings beat was detected and verified against independent data sources. It draws on 20 tracked change events for ILMN, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of October 30, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.

Data sources
FMP real-time & historical price dataFMP earnings & estimatesCompany news feedsAnalyst ratings & price targets (FMP)SEC EDGAR filingsEarnings calendar (FMP)
Educational research tool — not personalized investment advice. Data may be delayed.